Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy

Soheilifar, Mohammad Hasan; Taheri, Ramezan Ali; Emameh, Reza Zolfaghari; Moshtaghian, Abdolvahab; Kooshki, Hamid; Motie, Mohammad Reza

doi:10.1016/j.biopha.2018.04.117

Cited by 26 publications

(16 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overexpression of PD‐1 is well demonstrated in cancers, whereas low expression of this molecule may cause intolerance to self‐tissue in autoimmune diseases (Chodon, Koya, & Odunsi, ; Dai, Jia, Zhang, Fang, & Huang, ). The genetic risk factors have the strong association with increased risk of cancers such as BCC (Chahal et al, ; Soheilifar et al, ; Stacey et al, ). SNP, as the most common genetic variation, contributes to the molecular pathogenesis of complex diseases via different functional mechanisms including effect on RNA splicing, transcription factor binding, DNA methylation at promoters, miRNAs binding to its target mRNA and long noncoding RNAs (Salmaninejad et al, ).…”

Section: Discussionmentioning

confidence: 99%

Association of programmed death‐1 gene polymorphisms with the risk of basal cell carcinoma

Fathi

Ebrahimi

Eslami

et al. 2019

Int J Immunogenetics

View full text Add to dashboard Cite

Environmental and genetic factors play a fundamental role in the pathogenesis of basal cell carcinoma (BCC) defined as the most common cancer of skin. Programmed death‐1 (PD‐1), encoded by programmed cell death‐1 (PDCD1) gene, serves as an inhibitory molecule in the suppression of immune responses and a risk factor in the development of different cancers. In this study, we investigated the role of two single nucleotide polymorphisms (SNPs) within PDCD1 gene, and haplotypes defined by these SNPs, in the development of BCC in an Iranian population. Whole blood samples were obtained from 210 BCC and 320 healthy subjects. Genomic DNA was extracted from whole blood samples, polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) was used to genotype determinations of PD1.3 (rs11568821) and PD1.5 (rs2227981) SNPs, and 4 haplotypes were constructed by PDCD1 SNPs. The frequency of G allele of PD1.3 was significantly higher in BCC patients than healthy subjects (p < 0.02), while these significant differences were not observed in the frequencies of PD1.5 alleles between BCC and healthy subjects. Moreover, we found that there were no statistically significant differences in PD1.3 and PD1.5 genotypes between BCC and control groups. Of all estimated haplotypes for PDCD1, only AC haplotype was associated with BCC (OR = 0.22, 95% CI = 0.06–0.79, p < 0.01). These findings suggest that PD1.3G allele and AC haplotype of PDCD1 contribute to BCC in the Iranian population. However, further studies in different populations with larger sample size are required to confirm this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of programmed death‐1 gene polymorphisms with the risk of basal cell carcinoma

Fathi

Ebrahimi

Eslami

et al. 2019

Int J Immunogenetics

View full text Add to dashboard Cite

show abstract

“…Formazan crystals were solubilised in dimethylsulfoxide (DMSO, Sigma Aldrich V R , St. Louis, MO), and absorbance rates were measured at 562 nm in ThermoPlate V R TP Reader. Chalcones 1,6,8,9,11,17,19, and 20 had the highest antiproliferative activity and were assayed against both cell lines at seven concentrations, ranging from 1.25 to 80 lM for IC 50 values determination.…”

Section: Antiproliferative Activity Of Chalcones 1-20mentioning

confidence: 99%

“…ER-positive cancer treatments include ER modulators, such as tamoxifen or aromatase inhibitors. HER2-positive cancer is treated with monoclonal antibodies, such as trastuzumab, which is administered alongside tyrosine-kinase inhibitors [7][8][9] . TNBC cancer treatment is focused on cytotoxic agents, such as taxanes or doxorubicin.…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells

Santos

Anselmo

Oliveira

et al. 2019

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Chalcones are valuable structures for drug discovery due to their broad bioactivity spectrum. In this study, we evaluated 20 synthetic chalcones against estrogen-receptor-positive breast cancer cells (MCF-7 line) and triple-negative breast cancer (TNBC) cells (MDA-MB-231 line). Antiproliferative screening by MTT assay resulted in two most active compounds: 2-fluoro-4'-aminochalcone (11) and 3-pyridyl-4'-aminochalcone (17). Their IC 50 values ranged from 13.2 to 34.7 mM against both cell lines. Selected chalcones are weak basic compounds and maintained their antiproliferative activity under acidosis conditions (pH 6.7), indicating their resistance to ion-trapping effect. The mode of breast cancer cells death was investigated and chalcones 11 and 17 were able to induce apoptosis rather than necrosis in both lines. Antiproliferative target investigations with MCF-7 cells suggested 11 and 17 upregulated p53 protein expression and did not affect Sp1 protein expression. Future studies on chalcones 11 and 17 can define their in vivo therapeutic potential.

show abstract

“…Normal stem cells have self-renewal and pluripotency properties, which are similar to CSCs as a small portion of tumor cells in tumor mass (17). CSCs are involved in tumorigenesis, metastasis, chemoradiotherapy resistance, and tumor relapse (18,19). Increasing evidences have shown that BMI1 plays a significant role in the proliferation, selfrenewal, and differentiation of several types of human stem and progenitor cells (12).…”

Section: Bmi1 As An Epigenetic Repressor Plays An Important Role In Tmentioning

confidence: 99%

BMI1 Roles in Cancer Stem Cells and Its Association with MicroRNAs Dysregulation in Cancer: Emphasis on Colorectal Cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Context: Colorectal cancer (CRC) is among the most common cancers in the world. Despite the existence of different treatment strategies such as chemoradiation and surgery, CRC therapy still remains a significant challenge as a result of the existence of cancer stem cells (CSCs). Evidence Acquisition: This review is comprised of research and review studies published in valid databases such as PubMed, Sci-enceDirect, Medline, Google Scholar, and Scopus, using the following keywords: BMI1, cancer stem cell, microRNA, and colorectal cancer. Results: BMI1 (B cell-specific Moloney murine leukemia virus integration site 1) is a key component of polycomb repressor complex 1 (PRC1) and plays a significant role in CSCs self-renewal in various types of cancer including CRC. It has been proven that BMI1, in association with deregulated microRNAs (miRNAs), can promote cell cycle progression as well as epithelial to mesenchymal transition (EMT) in cancer. Conclusions: BMI1 is a colon stem cell marker that is up-regulated in colon CSCs and can be taken as a promising target for CRC therapy. This review describes the role of BMI-1 in the self-renewal of CSCs and EMT in association with miRNA dysregulation (with emphasis on CRC).

show abstract

Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy

Cited by 26 publications

References 102 publications

Association of programmed death‐1 gene polymorphisms with the risk of basal cell carcinoma

Association of programmed death‐1 gene polymorphisms with the risk of basal cell carcinoma

Antiproliferative activity and p53 upregulation effects of chalcones on human breast cancer cells

BMI1 Roles in Cancer Stem Cells and Its Association with MicroRNAs Dysregulation in Cancer: Emphasis on Colorectal Cancer

Contact Info

Product

Resources

About